Thank you, David, and good morning. I will cover four key topics in my remarks this morning. First, an update on our third quarter results. Second, I'll discuss cash flow, the balance sheet, and capital deployment. After that, I will provide an updated financial outlook for 2026. And finally, I will share some headwinds and tailwinds as we look ahead to 2027. Our third quarter results demonstrate the discipline with which we continue to manage the enterprise. We once again delivered on our commitments and raised our full year outlook for revenue, adjusted EPS, and cash flow from operations. Our execution has significantly strengthened our balance sheet, allowing us to achieve target leverage ahead of schedule and will enable us to resume our share repurchase program in the fourth quarter. ? Let me start by highlighting some of our enterprise results in the quarter. We generated over $108 billion of revenue and delivered nearly $4.2 billion of adjusted operating income, once again reflecting earnings growth across all of our operating segments. ? We delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. And finally, in the quarter, we generated cash flow from operations of approximately $4.7 billion, bringing our year-to-date cash flow from operations to $15.3 billion. Turning now to each of our segments in health care benefits, we continue to make strong progress in our return to target margins. In the quarter, we delivered adjusted operating income of approximately $900 million, an increase of nearly $600 million from the prior year quarter. Our medical benefit ratio was 91.3%, in improvement of approximately 150 basis points from the prior year. These results were primarily driven by improved underlying performance in our Medicare business. Across our businesses, we continue to successfully navigate elevated trends that remain above historical levels throughout the industry, but were broadly in line with our expectations. Performance in our Medicare book modestly exceeded our expectations, driven by pockets of favorability as a result of strong medical cost management and discipline pricing. ? We remain confident in the adequacy of our reserves. ? In our health services segment, we continue to execute against our objectives. During the quarter, we delivered adjusted operating income of $2.1 billion, an increase of nearly 3% from the prior year quarter, primarily driven by improved purchasing economics and pharmacy drug mix, partially offset by continued pharmacy client price improvements. Results in our pharmacy services business were in line with our expectations during the quarter, including performance in both our 340B business and rebate guarantees. Healthcare delivery also performed as expected as we continue to drive improvement in the business. Our pharmacy and consumer wellness segment delivered another strong quarter. We generated adjusted operating income of over $1.6 billion, an increase of over 10% from the prior year, primarily driven by core pharmacy strength, including a nearly 4% increase in same store prescription volumes, partially offset by continued business investments and the impact of consumer dynamics. Turning now to cash flow and the balance sheet, year to date, we have generated cash flow from operations of $15.3 billion, reflecting strong earnings as well as the impact of improvements in working capital. So far in 2026, we have returned nearly $2.6 billion to our shareholders through our shareholder dividend. We ended the quarter with nearly $6 billion of cash at the parent and unrestricted subsidiaries. As I mentioned earlier, we have made significant progress strengthening our balance sheet and have achieved our leverage goal ahead of schedule. This improved position, combined with our strong cash flow, will enable us to resume our share repurchase program in the fourth quarter. Shifting now to our guidance for 2026, we are increasing our full year 2026 guidance for adjusted EPS to at least $8.20, an increase of 20 cents from the midpoint of our previous outlook. We now also expect our full year total revenues to be at least $420 billion. ? In our health care benefits segment, we now expect full-year adjusted operating income to be at least $5.4 billion, an increase of $200 million relative to the midpoint of our prior outlook. We now expect our full year MBR to be in the lower half of our previously discussed range of $89.75%, plus or minus 25 basis points. This outlook continues to maintain a respectful and prudent view of medical cost trends. In our pharmacy and consumer wellness segment, we now expect full year adjusted operating income of at least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% growth from the prior year. This reflects our strong performance in the quarter and our updated expectations for the remainder of the year. We are also reiterating our full year adjusted operating income outlook for our health services segment. In aggregate, we now expect full year enterprise adjusted operating income to be at least $17.05 billion. We are also increasing our outlook for full year cash flow from operations to at least $15.5 billion, reflecting our updated earnings outlook as well as the impact of working capital improvements and the timing of certain payments. Cash generation has long been a strength of this enterprise, and we continue to build on that strength as we deliver on our embedded earnings and unlock further working capital efficiencies. ? You can find additional details on the components of our updated 2026 guidance on our investor relations website. Turning now to 2027, consistent with past practice, we expect to provide formal 2027 guidance on our fourth quarter earnings call early next year. Today I will share an update on some of the key headwinds and tailwinds we are considering for 2027. Starting first with our health care benefits business, we expect another year of meaningful margin improvement as Aetna makes strong progress on its path back to target margins. Once again, this improvement will be largely driven by the deliberate actions we took in our Medicare Advantage business, along with continued disciplined underwriting and pricing across our businesses in response to the elevated trend environment we expect will persist in 2027. In our health services segment, we expect to generate adjusted operating income of at least $7 billion. This includes our previously discussed expectations for a year-on-year decline in our 340B business, as well as headwinds from the impact of a less robust selling season and health plan client membership attrition. We also expect tailwinds from continued strength in specialty and another year of improvement in our health care delivery business. We continue to expect our 340B business to largely stabilize by the end of next year, and we have confidence as we enter the 2028 PBM selling season. ? We are confident 2027 will reflect trough earnings for the segment and we expect to return to growth from there. In our pharmacy and consumer wellness business, we expect adjusted operating income to grow low single digits off our current 2026 guidance of at least $6.5 billion driven by continued pharmacy strength. This marks the third consecutive year of growth in earnings for this segment. Our updated outlook reflects the progress we've made, differentiating our business and solidifying our position as the best run national pharmacy while maintaining a prudent view of consumer dynamics. Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline.
Passages & reports (39) 4:35 Thank you, David, and good morning. I will cover four key topics in my remarks this mornin… Report 4:54 tailwinds as we look ahead to 2027. Our third quarter results demonstrate the discipline w… Report 5:14 has significantly strengthened our balance sheet, allowing us to achieve target leverage a… Report 5:25 Let Report 5:25 me start by highlighting some of our enterprise results in the quarter. We generated over … Report 5:43 We Report 5:43 delivered adjusted EPS of $2.09, an increase of over 30% from the prior year quarter. And … Report 6:03 billion. Turning now to each of our segments in health care benefits, we continue to make … Report 6:23 quarter. Our medical benefit ratio was 91.3%, in improvement of approximately 150 basis po… Report 6:43 we continue to successfully navigate elevated trends that remain above historical levels t… Report 7:03 discipline pricing. Report 7:05 We Report 7:05 remain confident in the adequacy of our reserves. Report 7:09 In Report 7:09 our health services segment, we continue to execute against our objectives. During the qua… Report 7:29 offset by continued pharmacy client price improvements. Results in our pharmacy services b… Report 7:49 improvement in the business. Our pharmacy and consumer wellness segment delivered another … Report 8:09 a nearly 4% increase in same store prescription volumes, partially offset by continued bus… Report 8:28 billion, reflecting strong earnings as well as the impact of improvements in working capit… Report 8:48 unrestricted subsidiaries. As I mentioned earlier, we have made significant progress stren… Report 9:08 quarter. Shifting now to our guidance for 2026, we are increasing our full year 2026 guida… Report 9:28 revenues to be at least $420 billion. Report 9:31 In Report 9:32 our health care benefits segment, we now expect full-year adjusted operating income to be … Report 9:51 range of $89.75%, plus or minus 25 basis points. This outlook continues to maintain a resp… Report 10:11 least $6.5 billion, an increase of $100 million from our prior guidance and nearly 8% grow… Report 10:31 year adjusted operating income outlook for our health services segment. In aggregate, we n… Report 10:50 operations to at least $15.5 billion, reflecting our updated earnings outlook as well as t… Report 11:10 embedded earnings and unlock further working capital efficiencies. Report 11:15 You Report 11:16 can find additional details on the components of our updated 2026 guidance on our investor… Report 11:36 some of the key headwinds and tailwinds we are considering for 2027. Starting first with o… Report 11:56 deliberate actions we took in our Medicare Advantage business, along with continued discip… Report 12:16 at least $7 billion. This includes our previously discussed expectations for a year-on-yea… Report 12:35 continued strength in specialty and another year of improvement in our health care deliver… Report 12:53 We Report 12:53 are confident 2027 will reflect trough earnings for the segment and we expect to return to… Report 13:13 by continued pharmacy strength. This marks the third consecutive year of growth in earning… Report 13:33 of consumer dynamics. Pulling it all together and reflecting the strong performance we saw… Report